Stone House Investment Management’s Rapport Therapeutics RAPP Stock Holding History

Stone House Investment Management’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.79K	Buy	+211	New	+$7.75K	﹤0.01%	453

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Stone House Investment Management's RAPP Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 211 shares worth $8.79K. The stake represents ﹤0.01% of the portfolio and ranks #453 among its holdings.

161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

Stone House Investment Management held 211 shares of Rapport Therapeutics worth $8.79K as of Q2 2026.
Rapport Therapeutics was a new Stone House Investment Management position in Q2 2026.
Rapport Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #453 holding.
161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.